School of Medicine
Showing 4,161-4,180 of 4,414 Results
Assistant Professor of Genetics and of Pathology
Current Research and Scholarly Interests Our laboratory uses genome-wide methods to uncover alterations that drive cancer progression and metastasis in genetically-engineered mouse models of human cancers. We combine cell-culture based mechanistic studies with our ability to alter pathways of interest during tumor progression in vivo to better understand each step of metastatic spread and to uncover the therapeutic vulnerabilities of advanced cancer cells.
Social Sci Res Assoc, Medicine - Med/Stanford Prevention Research Center
Current Role at Stanford Research Associate with the Stanford Prevention Research Center
Program Director of the Well Living Laboratory
Professor of Radiology (General Radiology) and, by courtesy, of Neurology and of Neurosurgery at the Stanford University Medical Center
Current Research and Scholarly Interests Stroke, cerebrovascular diseases, cardiovascular diseases, carotid arteries, coronary arteries
Stroke diagnosis, stroke triage, stroke treatment
Traumatic brain injury
Traumatic brain injury diagnosis and prognosis
Psychiatric disorders, including depression and post-traumatic stress disorders
Movement disorders, including essential tremor and Parkinson’s tremor
Image-guided clinical trials
CT, multidetector-row CT, perfusion-CT, CT angiography
MRI, diffusion-weighted MRI, perfusion-weighted MRI, diffusion tensor imaging, functional MRI
Brain perfusion imaging techniques
Post-processing techniques of medical images, signal and image processing
MR-guided focused ultrasound
Paul H. Wise, MD, MPH
Richard E. Behrman Professor in Child Health and Professor, by courtesy, of Health Research and Policy
Current Research and Scholarly Interests He is a health policy and outcomes researcher whose work has focused on children's health; health-outcomes disparities by race, ethnicity and socioeconomic status; the interaction of genetics and the environment as these factors influence child and maternal health; and the impact of medical technology on disparities in health outcomes.
Postdoctoral Research fellow, Radiology
Bio Tim Witney is a Post-Doctoral Scholar and member of the Molecular Imaging Program at Stanford University.
He joined Professor Sanjiv Sam Gambhir's lab at Stanford in 2013, building on 3 years of postdoctoral research in biomedical imaging at Imperial College London and doctoral training at the University of Cambridge. His research interests include the discovery and development of new PET and MR methods to image tumour metabolism and the down-stream effect of targetted therapeutics. The development of a new generation of molecular imaging techniques will focus on early cancer detection, assess the efficacy of novel and preexisting cancer therapeutics and help describe the fundamental biological mechanisms that drive treatment resistance.
He was a finalist in MedImmune's 2009 Oncology Competition and has previously worked as a Research Biologist at GE Healthcare.
His blog on cancer imaging can be found at http://cancerimaging.blogspot.co.uk/
Assistant Professor of Medicine (Cardiovascular Medicine) at the Stanford University Medical Center
Current Research and Scholarly Interests 1) Understanding, treating, and preventing cancer therapy-induced cardiotoxicity
2) Amyloidosis -- Optimizing therapy and discovering new treatments
3) Relationships between insulin resistance and dilated cardiomyopathy
Yohannes Woubishet Woldeamanuel
Postdoctoral Research fellow, Neurology and Neurological Sciences
Current Research and Scholarly Interests Impact of Regular Lifestyle Behavior Modification in Migraine Burden
Albert J. Wong, M.D.
Professor of Neurosurgery
Current Research and Scholarly Interests Our goal is to define targets for cancer therapeutics by identifying alterations in signal transduction proteins. We first identified a naturally occurring mutant EGF receptor (EGFRvIII) and then delineated its unique signal transduction pathway. This work led to the identification of Gab1 followed by the discovery that JNK is constitutively active in tumors. We intiated using altered proteins as the target for vaccination, where an EGFRvIII based vaccine appears to be highly effective.